[go: up one dir, main page]

WO2014011911A3 - Irak inhibitors and uses thereof - Google Patents

Irak inhibitors and uses thereof Download PDF

Info

Publication number
WO2014011911A3
WO2014011911A3 PCT/US2013/050120 US2013050120W WO2014011911A3 WO 2014011911 A3 WO2014011911 A3 WO 2014011911A3 US 2013050120 W US2013050120 W US 2013050120W WO 2014011911 A3 WO2014011911 A3 WO 2014011911A3
Authority
WO
WIPO (PCT)
Prior art keywords
irak inhibitors
irak
inhibitors
furano
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/050120
Other languages
French (fr)
Other versions
WO2014011911A2 (en
Inventor
Geraldine C. Harriman
Donna L. Romero
Craig E. Masse
Shaughnessy Robinson
Matthew David Wessel
Jeremy Robert Greenwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nimbus Iris Inc
Original Assignee
Nimbus Iris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Iris Inc filed Critical Nimbus Iris Inc
Publication of WO2014011911A2 publication Critical patent/WO2014011911A2/en
Anticipated expiration legal-status Critical
Publication of WO2014011911A3 publication Critical patent/WO2014011911A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides furano- and pyrrolo- pyrimidine and pyridine compounds, compositions thereof, and methods of using the same.
PCT/US2013/050120 2012-07-11 2013-07-11 Irak inhibitors and uses thereof Ceased WO2014011911A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261670386P 2012-07-11 2012-07-11
US61/670,386 2012-07-11
US201261682616P 2012-08-13 2012-08-13
US61/682,616 2012-08-13

Publications (2)

Publication Number Publication Date
WO2014011911A2 WO2014011911A2 (en) 2014-01-16
WO2014011911A3 true WO2014011911A3 (en) 2015-07-16

Family

ID=49914495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/050120 Ceased WO2014011911A2 (en) 2012-07-11 2013-07-11 Irak inhibitors and uses thereof

Country Status (2)

Country Link
US (1) US20140018361A1 (en)
WO (1) WO2014011911A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
TW201728592A (en) 2012-01-10 2017-08-16 林伯士艾瑞斯公司 IRAK inhibitors and uses thereof
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107501275B (en) 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitor
EP2943202A4 (en) 2013-01-10 2016-08-24 Nimbus Iris Inc Irak inhibitors and uses thereof
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
PE20151764A1 (en) 2013-02-22 2015-12-03 Pfizer DERIVATIVES OF PIRROLO [2,3-D] PYRIMIDINE
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP6426694B2 (en) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド Compounds for the modification of hemoglobin and their use
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512239A (en) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
PT3077397T (en) 2013-12-06 2020-01-22 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015164374A1 (en) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6568111B2 (en) 2014-06-05 2019-08-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Radiolabeled derivatives of 2-amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide compounds useful as ATR kinase inhibitors, Preparation of compounds and their different solid forms
HRP20191375T1 (en) 2014-06-17 2019-11-01 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
GB201411236D0 (en) 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
KR102523430B1 (en) 2014-08-04 2023-04-19 누에볼루션 에이/에스 Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
ES2750655T3 (en) 2014-08-12 2020-03-26 Pfizer Pyrrolo [2,3-d] pyrimidine derivatives useful to inhibit Janus kinase
EP3200788B1 (en) * 2014-09-30 2019-09-18 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
CN114057765A (en) 2015-02-02 2022-02-18 瓦洛健康股份有限公司 3-Aryl-4-amido-bicyclo[4,5,0]hydroxamic acids as HDAC inhibitors
AR103598A1 (en) 2015-02-02 2017-05-24 Forma Therapeutics Inc BICYCLIC ACIDS [4,6,0] HYDROXAMICS AS HDAC INHIBITORS
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017024589A1 (en) * 2015-08-13 2017-02-16 北京韩美药品有限公司 Irak4 inhibitor and use thereof
CN107531710B (en) * 2015-08-13 2020-02-14 北京韩美药品有限公司 IRAK4 inhibitor and application thereof
WO2017025849A1 (en) * 2015-08-13 2017-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
RU2768621C1 (en) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Method of treating cancer using a combination of dna damaging agents and atr inhibitors
SG10201508795XA (en) * 2015-10-23 2017-05-30 Agency Science Tech & Res Method for treating cancer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN105461728A (en) * 2015-12-29 2016-04-06 中山大学 4-substituted amino-6-methoxycarbonyl group benzofuran and [2,3-d] pyrimidine compound and preparing method
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
JP2019530650A (en) 2016-08-24 2019-10-24 アークル インコーポレイテッド Amino-pyrrolopyrimidinone compounds and methods of use thereof
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc Perulo derivatives [1, 2-b] pyridazine
WO2019001461A1 (en) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 INHIBITOR OF IRAQ4
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
MX2020003190A (en) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Protein degraders and uses thereof.
AU2018373258B2 (en) 2017-11-27 2023-03-02 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADING AGENTS AND THEIR USES
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TWI721483B (en) 2018-07-13 2021-03-11 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
CN111662295B (en) * 2019-03-05 2021-09-10 珠海宇繁生物科技有限责任公司 IRAK4 kinase inhibitor and preparation method thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. IRAQ DEGRADATION AGENTS AND THEIR USES
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
PE20230240A1 (en) 2019-12-20 2023-02-07 Nuevolution As ACTIVE COMPOUNDS AGAINST NUCLEAR RECEPTORS
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
TW202241891A (en) 2020-12-30 2022-11-01 美商凱麥拉醫療公司 Irak degraders and uses thereof
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
JP2024519215A (en) 2021-05-07 2024-05-09 カイメラ セラピューティクス， インコーポレイテッド CDK2 degraders and their uses
TW202334165A (en) 2021-10-29 2023-09-01 美商凱麥拉醫療公司 Irak4 degraders and synthesis thereof
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2024107393A1 (en) * 2022-11-14 2024-05-23 Schrödinger, Inc. Tricyclic compounds
CN116731030A (en) * 2023-06-07 2023-09-12 湖北医药学院 Synthesis method and antitumor application of several furopyrimidine-ibuprofen hybrid derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US20100143341A1 (en) * 2005-06-22 2010-06-10 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
US8058285B2 (en) * 2004-07-23 2011-11-15 The Medicines Company (Leipzig) Gmbh Substituted pyrido [3′, 2′: 4, 5] thieno [3, 2-D] pyrimidines and pyrido [3′, 2′: 4, 5] furo [3, 2-D] pyrimidines used as inhibitors of the PDE-4 and/or the release of TNF-ALPHA
WO2012007375A1 (en) * 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680322B2 (en) * 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US8058285B2 (en) * 2004-07-23 2011-11-15 The Medicines Company (Leipzig) Gmbh Substituted pyrido [3′, 2′: 4, 5] thieno [3, 2-D] pyrimidines and pyrido [3′, 2′: 4, 5] furo [3, 2-D] pyrimidines used as inhibitors of the PDE-4 and/or the release of TNF-ALPHA
US20100143341A1 (en) * 2005-06-22 2010-06-10 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2012007375A1 (en) * 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NGO, VN ET AL.: "Oncogenically active MYD88 mutations in human lymphoma.", NATURE, vol. 470, no. 7332, 22 December 2010 (2010-12-22), pages 115 - 119, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/21179087> [retrieved on 20131129] *
SONG, KW ET AL.: "The kinase activities of Interleukin-1 receptor associated kinase ( IRAK )-1 and 4 are redundant in the control of Inflammatory cytokine expression in human cells.", MOL IMMUNOL, vol. 46, no. 7, 31 January 2009 (2009-01-31), pages 1458 - 1466, Retrieved from the Internet <URL:http://www.ncbi.nim.nih.gov/pubmed/19161383> [retrieved on 20131129] *

Also Published As

Publication number Publication date
US20140018361A1 (en) 2014-01-16
WO2014011911A2 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
WO2014011911A3 (en) Irak inhibitors and uses thereof
WO2014011906A3 (en) Irak inhibitors and uses thereof
HK1210696A1 (en) Irak inhibitors and uses thereof
HK1216859A1 (en) Irak inhibitors and uses thereof
HK1217410A1 (en) Erk inhibitors and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
MX2016003843A (en) Irak inhibitors and uses thereof.
HK1221660A1 (en) Acc inhibitors and uses thereof
HK1221659A1 (en) Acc inhibitors and uses thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2017050791A8 (en) New bicyclic compounds as dual atx/ca inhibitors
WO2014015251A3 (en) Tissue-engineered pumps and valves and uses thereof
WO2012021444A8 (en) Besylate salt of a btk inhibitor
WO2018006074A3 (en) Compounds and methods for modulating rna function
HK1209768A1 (en) Antibodies to tau
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2012158843A3 (en) Kinase inhibitors
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
WO2015013465A3 (en) Methods and compositions for detecting bacterial contamination
WO2015069847A3 (en) Co-culture based modular engineering for the biosynthesis of isoprenoids, aromatics and aromatic-derived compounds
WO2015077657A3 (en) Stat3 inhibitors and uses thereof
WO2013164839A8 (en) Amorphous form of apixaban, process of preparation and compositions thereof
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2015197534A3 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3066167A4 (en) Primerless paint composition, methods of manufacture thereof and articles comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13816361

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13816361

Country of ref document: EP

Kind code of ref document: A2